Cytori Therapeutics (CYTX)

Business description

Cytori sells the Celution device to harvest and concentrate adipose cells at the bedside for autologous therapy. It is CE marked. Two cardiac studies are underway in heart attack recovery and chronic heart disease.

Share price chart

Share chart

Stock data

Market cap.US$59.2m
Last closeUS$0.74
High / Low (52 weeks)US$3.4 / US$0.7
Stock market listingUS
Forecast net debt (US$m)31.8
Forecast gearing ratio (%)141
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual(47.2)(69)(69.4)
Relative *(46.6)(69.3)(73.8)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Achillion Pharmaceuticals Acorda Therapeutics
Actinium Pharmaceuticals Active Biotech
Addex Therapeutics Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
Agennix Alchemia
Alexza Pharmaceuticals Algeta
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Alnylam Pharmaceuticals Amarantus BioScience
Amarin AmpliPhi Biosciences
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Arena Pharmaceuticals
Argos Therapeutics Ariad Pharmaceuticals
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Astex Pharmaceuticals Athersys
AVEO Pharmaceuticals Avita Medical
Basilea Bavarian Nordic
Bellus Health Benitec Biopharma
BioAlliance Pharma BioCryst Pharmaceuticals
BioInvent BioLight Life Sciences Inv
BioLineRx Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio BTG
Can-Fite BioPharma Capstone Therapeutics
Cardio3 BioSciences CARMAT
Celldex Therapeutics Cellectis
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen
Clinuvel Consort Medical
Curis Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics EKF Diagnostics
Endocyte Epigenomics
Epistem Holdings Erytech Pharma
Esperion Therapeutics Evolva
Evotec Exact Sciences
Exelixis Formycon
Futura Medical Galapagos
Galmed Pharmaceuticals Genfit
Genmab GeoVax
GI Dynamics Gilead Sciences
GW Pharmaceuticals Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunodiagnostic Systems Holdings ImmuPharma
Imugene Incyte Corporation
Infinity Pharmaceuticals Innate Pharma
Insmed Invion
Ion Beam Applications Ipsogen
Ironwood Pharmaceuticals Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals LCA-Vision
LeMaitre Vascular Lifeline Scientific
Ligand Pharmaceuticals Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
MolMed Mologen AG
MorphoSys Nanobiotix
Nanosonics Nektar Therapeutics
Neovacs Newron Pharmaceuticals
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novogen
NPS Pharmaceuticals Omega Diagnostics Group
Omeros Corporation OncoGenex Pharmaceuticals
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onyx Pharmaceuticals OPMEDIC Group
Optos Orexigen Therapeutics
Orexo OvaScience
Oxford BioMedica Pacific Edge
Paion Paladin Labs
Patheon Pharmacyclics
Pharmaxis Pharming Group
Photocure Phylogica
Prima BioMed ProMetic Life Sciences
Prosensa Proteome Sciences
QRxPharma Regeneus
ReNeuron Group Resverlogix
REVA Medical Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis Synairgen
Synergy Health Synta Pharmaceuticals
Tekmira TESARO
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Topotarget
Transgene Trillium Therapeutics
Trimel Pharmaceuticals UCB
uniQure NV United Drug
Vectura Verastem
Verisante Technology Vernalis
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus WaferGen Biosystems
Wilex Xencor
Zafgen Zealand Pharma
Zeltia Ziopharm Oncology
Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2012A 14.5 (28.4) (33.0) (56.3) N/A N/A
2013A 12.2 (32.6) (38.1) (56.2) N/A N/A
2014E 12.4 (35.3) (40.2) (53.5) N/A N/A
2015E 33.3 (22.9) (27.0) (35.9) N/A N/A

Last updated on 19/09/2014

Investment summary

Cytori has gained new a $12m BARDA contract for a thermal burns indication for its patient-derived adipose (fat) derived regenerative cells (ADRC). Any trial would gain a further $8.3m in support, making $20.4m in total. The ATHENA ischemic cardiomyopathy trial (40m and 80m cell dose arms) has been put on hold due to three cerebrovascular events, two of which resolved fully and one substantially. It is not certain when the trial will resume. Six-month contract revenues were $2.7m with $3.6m of sales due to be recognised in H214. Cash and equivalents on 30 June stood at $12.8m. Cytori raised $10m gross in a June share subscription.

Last updated on 30/09/2014

Industry outlook

Cardio3 (autologous) and Teva/Mesoblast (allogenic) both have Phase III studies in chronic ischemic heart disease under way. A small study in anterior cruciate ligament repair has completed recruitment. A 12-patient Scleroderma study reduced hand disability and pain. EU operations are being consolidated to a new office and manufacturing facility in Wales, UK.

Last updated on 30/09/2014

Key management

Christopher Calhoun , CEO
Mark Saad , CFO

Company address

3020 Callan Road
San Diago
CA 92121
United States
+1.858.458.0900
View website